JP7767428B2 - ポリペプチド及びその使用 - Google Patents

ポリペプチド及びその使用

Info

Publication number
JP7767428B2
JP7767428B2 JP2023536144A JP2023536144A JP7767428B2 JP 7767428 B2 JP7767428 B2 JP 7767428B2 JP 2023536144 A JP2023536144 A JP 2023536144A JP 2023536144 A JP2023536144 A JP 2023536144A JP 7767428 B2 JP7767428 B2 JP 7767428B2
Authority
JP
Japan
Prior art keywords
polypeptide
aib
diacid
amide
pharmaceutically acceptable
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2023536144A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023554046A (ja
JPWO2022129254A5 (enExample
Inventor
アレクサンドラ ベドナレック，マリア
ジェナパシー，シバネスワリ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
MedImmune Ltd
Original Assignee
MedImmune Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by MedImmune Ltd filed Critical MedImmune Ltd
Publication of JP2023554046A publication Critical patent/JP2023554046A/ja
Publication of JPWO2022129254A5 publication Critical patent/JPWO2022129254A5/ja
Application granted granted Critical
Publication of JP7767428B2 publication Critical patent/JP7767428B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/31—Fusion polypeptide fusions, other than Fc, for prolonged plasma life, e.g. albumin

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Diabetes (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Obesity (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
JP2023536144A 2020-12-16 2021-12-15 ポリペプチド及びその使用 Active JP7767428B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063125996P 2020-12-16 2020-12-16
US63/125,996 2020-12-16
PCT/EP2021/086034 WO2022129254A1 (en) 2020-12-16 2021-12-15 Polypeptides and uses thereof

Publications (3)

Publication Number Publication Date
JP2023554046A JP2023554046A (ja) 2023-12-26
JPWO2022129254A5 JPWO2022129254A5 (enExample) 2024-10-24
JP7767428B2 true JP7767428B2 (ja) 2025-11-11

Family

ID=79287870

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023536144A Active JP7767428B2 (ja) 2020-12-16 2021-12-15 ポリペプチド及びその使用

Country Status (16)

Country Link
US (3) US12371464B2 (enExample)
EP (1) EP4263586A1 (enExample)
JP (1) JP7767428B2 (enExample)
KR (1) KR20230120134A (enExample)
CN (1) CN116685599A (enExample)
AR (1) AR124391A1 (enExample)
AU (2) AU2021399076B2 (enExample)
CA (1) CA3204296A1 (enExample)
CL (1) CL2023001719A1 (enExample)
CO (1) CO2023009066A2 (enExample)
CR (1) CR20230311A (enExample)
EC (1) ECSP23052600A (enExample)
IL (1) IL303578A (enExample)
MX (1) MX2023007288A (enExample)
TW (1) TW202241933A (enExample)
WO (1) WO2022129254A1 (enExample)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20230120134A (ko) 2020-12-16 2023-08-16 메디뮨 리미티드 폴리펩티드 및 이의 용도
KR20240118914A (ko) 2021-01-20 2024-08-05 바이킹 테라퓨틱스 인코포레이티드 대사 및 간 질환 치료를 위한 조성물 및 방법
WO2023044290A1 (en) 2021-09-15 2023-03-23 Viking Therapeutics, Inc. Compositions and methods for the treatment of metabolic and liver disorders
US12116388B2 (en) 2022-12-22 2024-10-15 Novo Nordisk A/S Amylin receptor agonists
GB2641696A (en) * 2023-02-10 2025-12-10 Hangzhou Sciwind Biosciences Co Ltd Polypeptide and derivative thereof, composition, and use thereof
WO2025114501A1 (en) 2023-11-30 2025-06-05 Novo Nordisk A/S Tri-agonists of the glp-1, gip, and amylin receptors
WO2025147628A2 (en) * 2024-01-05 2025-07-10 Indiana University Research And Technology Corporation Dual amylin calcitonin receptor agonists
WO2025242620A1 (en) 2024-05-20 2025-11-27 Medimmune Limited Polypeptide combinations and uses thereof

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100221240A1 (en) 2004-10-20 2010-09-02 Fraunhofer-Gesellschaft Zur Forderung Der Angewandten Forschung E.V. Chemically Modified Peptide Analogs
US20200115430A1 (en) 2018-10-11 2020-04-16 Intarcia Therapeutics, Inc. Human amylin analog polypeptides and methods of use

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101400698A (zh) 2006-03-15 2009-04-01 诺沃-诺迪斯克有限公司 胰岛淀粉样多肽衍生物
EP2036923A1 (en) * 2007-09-11 2009-03-18 Novo Nordisk A/S Improved derivates of amylin
JP5703226B2 (ja) * 2008-10-21 2015-04-15 ノヴォ ノルディスク アー／エス アミリン誘導体
WO2011037970A1 (en) * 2009-09-22 2011-03-31 University Of Miami Podocyte ph modulation and uses thereof
WO2013059336A1 (en) 2011-10-18 2013-04-25 Amylin Pharmaceuticals, Llc Amylin-calcitonin chimeric peptides conjugated to duration enchancing moieties
CN105849123A (zh) * 2013-12-13 2016-08-10 免疫医疗有限公司 蛋白酶抗性肽
CN106999602B (zh) 2014-11-27 2022-02-01 诺和诺德股份有限公司 Glp-1衍生物及其用途
WO2020225781A1 (en) 2019-05-08 2020-11-12 Auckland Uniservices Limited Peptide conjugate amylin agonists and uses thereof
KR20230120134A (ko) 2020-12-16 2023-08-16 메디뮨 리미티드 폴리펩티드 및 이의 용도

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100221240A1 (en) 2004-10-20 2010-09-02 Fraunhofer-Gesellschaft Zur Forderung Der Angewandten Forschung E.V. Chemically Modified Peptide Analogs
US20200115430A1 (en) 2018-10-11 2020-04-16 Intarcia Therapeutics, Inc. Human amylin analog polypeptides and methods of use

Also Published As

Publication number Publication date
TW202241933A (zh) 2022-11-01
KR20230120134A (ko) 2023-08-16
MX2023007288A (es) 2023-07-03
WO2022129254A1 (en) 2022-06-23
ECSP23052600A (es) 2023-08-31
CN116685599A (zh) 2023-09-01
CL2023001719A1 (es) 2024-01-26
AR124391A1 (es) 2023-03-22
CO2023009066A2 (es) 2023-07-10
JP2023554046A (ja) 2023-12-26
CA3204296A1 (en) 2022-06-23
IL303578A (en) 2023-08-01
AU2024227071A1 (en) 2024-10-24
CR20230311A (es) 2023-09-01
AU2021399076B2 (en) 2024-07-11
US20220204580A1 (en) 2022-06-30
US20240067693A1 (en) 2024-02-29
AU2021399076A1 (en) 2023-07-27
US20250289860A1 (en) 2025-09-18
AU2021399076A9 (en) 2024-07-18
EP4263586A1 (en) 2023-10-25
US12371464B2 (en) 2025-07-29

Similar Documents

Publication Publication Date Title
JP7767428B2 (ja) ポリペプチド及びその使用
US8343914B2 (en) Fibrillation resistant proteins
JP6121330B2 (ja) 作用持続時間が増した改変ポリペプチド
CN103649115B (zh) 多肽
EP2932981B1 (en) Albumin-binding derivatives of GLP-1
US8501693B2 (en) Use of exendins and exendin agonists and GLP-1 receptor agonists for altering the concentration of fibrinogen
CN103596583B (zh) 新型胰高血糖素类似物
CN102197049B (zh) 胰岛淀粉样多肽衍生物
US20110059887A1 (en) Meal-time insulin analogues of enhanced stability
BR112020010244A2 (pt) análogos de incretina e seus usos
US20100099601A1 (en) Fibrillation-resistant insulin and insulin analogues
CN102933598A (zh) 新型胰高血糖素类似物
KR20120123443A (ko) 대사 장애 및 비만 치료용 글루카곤 길항제-ｇｉｐ 항진제 콘쥬게이트
JP2016521253A (ja) 持続性作用を有するプロドラッグ
CA2596926A1 (en) Extended glp-1 compounds
US20090209469A1 (en) Use of Exendins and GLP-1 Receptor Agonists for Altering Lipoprotein Particle Size and Subclass Composition
CN106687474A (zh) 新型胰淀素和降钙素受体激动剂
US20140128319A1 (en) Insulin analogues containing penta-fluoro-phenylalanine at position b24
JP2011525895A (ja) アミリン及びサケカルシトニンの誘導体化ハイブリッドペプチド
EA050089B1 (ru) Полипептиды и варианты их применения
AU2013237740B2 (en) Insulin analogues containing penta-fluora-phenyalanine at position B24

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20241015

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20241015

A871 Explanation of circumstances concerning accelerated examination

Free format text: JAPANESE INTERMEDIATE CODE: A871

Effective date: 20250227

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20250408

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250707

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20250930

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20251029

R150 Certificate of patent or registration of utility model

Ref document number: 7767428

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150